Psychiatric pharmacogenomic testing in clinical practice by Mrazek, David A.
linical pharmacogenomics consists of the appli-
cation of research that links measurable genetic variants
with the prediction of drug response.
1 Every medical
specialty can utilize the results of pharmacogenomic
probe studies to inform the adoption of individualized
pharmacotherapy. However, psychiatric pharmacother-
apy is particularly likely to benefit from the introduction
of pharmacogenomic testing, because there are many
psychotropic agents available for selection that target
specific symptoms.
The terms pharmacogenetics and pharmacogenomics
are currently used interchangeably. However, with the
growing understanding that multiple intragenic varia-
tions should be considered in making predictions related
to medication response, the use of the term pharma-
cogenomics has become more frequently chosen to des-
ignate the process of using documented genetic variation
to guide medication selection and dosing.
Historically, psychiatrists have used empirical strategies
to select medications. In the best practices, the choice of
medications has evolved based on a rational trial-and-
error process that has used clinical indicators to select
medications and then relied on documenting treatment
responses to titrate the optimal dose for a particular
patient. Psychiatrists learn to “start low and go slow” in
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The clinical adoption of psychiatric pharmacogenomic
testing has taken place rapidly over the past 7 years.
Initially, drug-metabolizing enzyme genes, such as the
cytochrome P450 2D6 gene (CYP2D6), were identified.
Genotyping the highly variable cytochrome P450 2D6
gene now provides clinicians with the opportunity to iden-
tify both poor metabolizers and ultrarapid metabolizers
of 2D6 substrate medications. Subsequently, genes influ-
encing the pharmacodynamic response of medications
have been made available for clinical practice. Among the
earliest “target genes” was the serotonin transporter
gene (SLC6A4) which has variants that have been shown
to influence the clinical response of patients of European
ancestry when they are treated with selective serotonin
reuptake inhibitors. Genotyping of some of the serotonin
receptor genes is also available to guide clinical practice.
The quantification of the clinical utility of pharmacoge-
nomic testing is evolving, and ethical considerations for
testing have been established. Given the increasingly clear
cost-effectiveness of genotyping, it has recently been pre-
dicted that pharmacogenomic testing will routinely be
ordered to guide the selection and dosing of psychotropic
medications.  
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trial of each medication. Unfortunately, these strategies
can result in a 3- to 4-week interval during which the
patient continues to experience symptoms. In recent
years, the potential iatrogenic harm associated with psy-
chotropic medications has become increasingly obvious,
with “black-box warnings” being attached to antide-
pressants, antipsychotic medications, stimulants, and
mood stabilizers.
Despite a growing awareness of this potential harm,
there are powerful pressures to try to accelerate the
achievement of therapeutic benefit. At the most basic
level, patients are impatient. They do not want to wait a
month to achieve symptom relief. Additionally, with an
increasing focus on the relief of specific symptoms,
strategies using multiple psychotropic medications have
become a standard of practice. Research supports the
common practice of augmenting an initial medication
with a second psychotropic drug.
2 However, there is no
scientifically available evidence to support the practice
of using four or five psychotropic medications simulta-
neously. Nevertheless, patients routinely receive multi-
ple psychotropic medications in an attempt to identify
the “right combination.” While some patients do achieve
a good therapeutic response using this trial-and-error
approach to individualized medicine, it is also true that
others become overmedicated or suffer from iatrogenic
side effects.
Pharmacogenomic testing provides an innovative strat-
egy to improve the likelihood of selecting an effective
psychotropic medication. The earliest medical texts rec-
ognize that individual patients experience quite dra-
matically different responses to the same drug. There is
also a longstanding observation that unusual drug
responses can occur in members of the same family. The
identification of specific gene variants associated with
idiosyncratic responses is about 50 years old,
3 and the
recognition that some psychiatric patients metabolize
antidepressants at dramatically different rates has been
documented for several decades.
4 However, with the use
of newer antidepressant medications that rarely have
life-threatening complications, the relatively expensive
practice of monitoring the serum levels of newer anti-
depressant medications has become uncommon in the
United States. This change has occurred despite the fact
that serum levels of these newer agents also have dra-
matic variations based on the metabolic capacity of each
patient.
A decade ago, the cost of genotyping began to become
more affordable, and individual laboratories initiated
pharmacogenomic testing that would provide genotyping
of individual cytochrome P450 genes. However, there was
no standard or well-validated methodology for the geno-
typing of these informative genes. There was also consid-
erable variability in the interpretation of the results. In
2004, the US Food and Drug Administration (FDA)
approved the use of a new product, the AmpliChip.
5The
introduction of the AmpliChip provided reference labo-
ratories with a standard method for identifying variations
in two of the cytochrome P450 genes: cytochrome P450
2D6 (CYP2D6) and cytochrome P450 2C19 (CYP2C19).
The approval of the AmpliChip was an important land-
mark in the history of psychiatric pharmacogenomic test-
ing, and within 3 years, CYP2D6 and CYP2C19 were
being genotyped by every reference laboratory in the
country. However, this advance also highlighted some of
the challenges associated with the introduction of clinical
testing. One of the most obvious challenges that must be
addressed is how to begin to assess new variants of these
two genes in updated versions of the assay. Ideally, the
methodology for establishing drug-metabolizing pheno-
types should be updated regularly based on new molecu-
lar genetic findings showing how new genotypic variants
influence gene function. Also, the clarification of the pre-
dictive capacity of previously identified gene variants
influencing gene function is similarly evolving, and newly
identified associations between gene structure and func-
tion should ideally be incorporated into algorithms that
define the metabolic capacity of psychiatric patients.
The evolution of pharmacogenomic research should
inform modifications in pharmacogenomic testing.
However, an implication of the rapid increase in our
knowledge base is that these new studies demonstrate
limitations in the accuracy of older genotyping method-
ologies that were designed prior to the discovery of
more recent variants. What is often not well appreciated
is that even older pharmacogenomic methods provided
important information for many patients, as these early
innovations were a major advance over psychopharma-
cological practice without pharmacogenomic insights.
However, as newer methodologies have further
improved the accuracy of the prediction of medication
response, the clinical utility of pharmacogenomic testing
continues to increase.
Pharmacogenomic testing in psychiatric practice initially
focused on identifying pharmacokinetic variability that
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ical genotypes. Pharmacokinetic variation influences 
the concentration of a drug at its sites of action.
Pharmacogenomic testing of drug-metabolizing enzyme
genes provides a prediction of how an individual patient
will metabolize a specific psychotropic medication. More
recently, the focus of pharmacogenomic testing has
expanded to include determining variability in the phar-
macodynamic response of a patient to a specific med-
ication. This variability reflects the capacity of the indi-
vidual patient to respond to adequate exposure to the
drug. Prediction of response is estimated based on the
documentation of variations in “target genes” that code
for receptors and transporters that influence the
response of the patient to a particular medication. 
This review will first identify the most widely genotyped
drug-metabolizing enzyme genes that influence the
pharmacokinetic metabolic capacity of a patient. Then,
it will focus on genes that influence the pharmacody-
namic responses of individual patients, before conclud-
ing with a brief discussion of the clinical utility of phar-
macogenomic testing and some of the ethical
considerations related to its routine use.
Pharmacogenomic testing to establish the
metabolic capacity of psychiatric patients
Many genes code for enzymes that influence drug
response. However, only the clinical implications of geno-
typing four of the most commonly tested cytochrome
P450 genes will be reviewed. The focus of this discussion
will be the clinical benefit for the patient of identifying
individualized molecular variations, and the implications
for those patients who have a quite significant decrement
in their capacity to metabolize specific psychotropic med-
ications. Identifying these individual patients provides
clinicians with a clear method of minimizing side effects.
This determination of decreased metabolic capacity is the
most obvious benefit of pharmacogenomic testing, but
implications of the pharmacogenomic testing for patients
with increased metabolic capacity will also be discussed,
as these patients are less likely to respond to specific psy-
chotropic medications.
The cytochrome P450 2D6 gene (CYP2D6)
CYP2D6 was the first drug-metabolizing enzyme gene
that was genotyped to identify psychiatric patients with
increased or decreased metabolic capacity. It is located
on chromosome 22 and consists of 4382 nucleotides.
CYP2D6 codes for an enzyme that is composed of 497
amino acids.
The CYP2D6 enzyme plays a primary role in the metab-
olism of more than 70 substrate medications, including
twelve psychotropic medications. CYP2D6 is one of the
most highly variable drug-metabolizing enzyme genes.
However, many of the other 29 P450 drug-metabolizing
enzyme genes are also highly variable. The specific
genetic variations that define variable phenotypes can
be located on a Web site maintained by the Karolinska
Institute (http://www.cypalleles.ki.se/). Each newly iden-
tified variant is included on the Web site after confir-
mation that it is unique.
There are currently 75 distinct CYP2D6 alleles posted
on this site, as well as an additional 55 CYP2D6 variants
that closely resemble one of the primary variants.
Traditionally, these variants have been classified as being
normal, deficient, or inactive drug-metabolizing alleles.
Additionally, some alleles have more recently been
demonstrated to code for an increased amount of
enzyme which enhances the metabolic activity of the
patient. Furthermore, patients can have a variable num-
ber of copies of CYP2D6. The most common number of
copies of CYP2D6 that patients carry is two. However,
some patients have only one copy and, rarely, none at all.
It is also possible to have more than two copies, and one
patient has been reported to have 13 copies.
4The devel-
opment of several different classification systems to cat-
egorize 2D6 substrate metabolic capacity of patients into
four phenotypic categories has been problematic. The
use of alternative methodologies by different research
teams has made it more difficult to study the implica-
tions of this variability.
The most important CYP2D6 phenotype to identify is
the poor 2D6 substrate metabolizer phenotype. Patients
who are poor metabolizers are at increased risk for
adverse events when they are prescribed 2D6 substrate
medications, because of their low metabolic capacity.
Patients are now classified as poor metabolizers if they
have two inactive alleles, or one inactive allele and one
deficient allele. 
The second most clinically important CYP2D6 pheno-
type is the ultrarapid metabolizer phenotype. Patients
are ultrarapid metabolizers if they have either three or
more active copies of CYP2D6 or two or more enhanced
copies of CYP2D6. They are unlikely to respond to 2D6
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ability to rapidly metabolize these medications makes it
difficult to sustain therapeutic serum levels.
The third clinically important CYP2D6 phenotype is the
intermediate metabolizer phenotype. These patients
have one normal copy of CYP2D6, and one copy that is
either deficient or inactive. While these patients can nor-
mally benefit from 2D6 substrate medications at low-to-
moderate doses, they are at increased risk for the devel-
opment of side effects at higher doses because of their
decreased metabolic capacity, and they are more at risk
for enzyme inhibition as a consequence of drug-drug
interactions. When intermediate metabolizers are
exposed to powerful 2D6 inhibitors such as paroxetine
or fluoxetine, their metabolic capacity can be further
decreased to the level of a poor metabolizer.
6
There are many psychotropic medications metabolized
by the 2D6 enzyme. Specifically, this enzyme:
￿ primarily metabolizes five antidepressants: fluoxetine,
paroxetine, venlafaxine, desipramine, and nortriptyline 
￿ substantially metabolizes amitriptyline, imipramine,
doxepin, duloxetine, trazodone, and mirtazapine
￿ primarily metabolizes risperidone and four of the typ-
ical antipsychotic medications: chlorpromazine, thior-
idazine, perphenazine, and haloperidol 
￿ has substantial involvement in the metabolism of arip-
iprazole and olanzapine
￿ primarily metabolizes atomoxetine and dextroam-
phetamine.
Beyond the prescription of psychotropic medications,
psychiatric patients are given many other 2D6 substrate
medications. Specifically, dextromethorphan is a cough
suppressant that is metabolized by the 2D6 enzyme.
Patients who are poor metabolizers of 2D6 substrate
medications are at increased risk for cognitive side effects
if taking standard doses of preparations that contain dex-
tromethorphan. Another example is codeine, which is a
prodrug. A prodrug must be converted to an active
metabolite in order to have a therapeutic effect. Patients
who are poor 2D6 metabolizers do not receive analgesic
benefit from codeine because they do not metabolize
codeine to morphine. Tamoxifen is also a prodrug that is
the most frequently prescribed treatment for breast can-
cer. Poor metabolizers have little or no benefit from
tamoxifen because they are not able to metabolize
tamoxifen to endoxifen.
7,8Additionally, paroxetine, flu-
oxetine, or bupropion should not be given to patients
who are receiving tamoxifen because they inhibit the
2D6 enzyme. Giving these inhibitors to intermediate
metabolizers can convert them to functional poor metab-
olizers. Consequently, they become unable to produce
endoxifen.
9
The cytochrome P450 2C19 gene (CYP2C19)
CYP2C19 was the second drug-metabolizing enzyme
gene that was widely genotyped to identify patients with
increased or decreased metabolic capacity. It is a large
gene located on chromosome 10. It consists of 90 209
nucleotides, but codes for an enzyme that contains only
490 amino acids.
The identification of patients with low 2C19 metabolic
capacity is clinically important because it allows clini-
cians to decrease the risk of iatrogenic side effects. 
The 2C19 enzyme:
￿ primarily metabolizes citalopram, escitalopram,
clomipramine, and amitriptyline 
￿ has substantial involvement in the metabolism of ser-
traline, imipramine, nortriptyline, and doxepin
￿ plays an important role in the metabolism of clozapine
and a minimal role in the metabolism of thioridazine
￿ is the primary enzyme involved in the metabolism of
diazepam. 
Recently, a new variant of CYP2C19 has been identified
which has enhanced function.
10 Patients who are
homozygous for this new allele are less likely to respond
to 2C19 substrate medications at standard doses. The
identification of ultrarapid 2C19 metabolizers can be
helpful in evaluating patients who do not respond to
standard doses of any of these psychotropic medications.
The cytochrome P450 2C9 gene (CYP2C9)
CYP2C9 is located on chromosome 10 in relative close
proximity to CYP2C19. However, it is only about half
the size of CYP2C9 as it consists of 50 708 nucleotides.
Like CYP2C19, CYP2C9 codes for an enzyme that con-
tains 490 amino acids.
CYP2C9 is a drug-metabolizing enzyme gene that is less
routinely genotyped to identify the increased or
decreased metabolic capacity of psychiatric patients for
2C9 substrate medications. It does not play a primary
role in the metabolism of any currently prescribed psy-
chotropic medications. However, the 2C9 enzyme pro-
vides the only secondary pathway for the metabolism of
fluoxetine, so patients who are poor metabolizers of
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both 2D6 substrates and 2C9 substrates are at very high
risk for adverse effects if treated with standard dose of
fluoxetine.
The cytochrome P450 1A2 gene (CYP1A2)
CYP1A2 is a less well-studied drug-metabolizing
enzyme gene, but it codes for an enzyme that plays an
important role in the metabolism of fluvoxamine. It is
also involved in the metabolism of duloxetine and olan-
zapine. CYP1A2 is located on chromosome 15 and con-
sists of 7758 nucleotides. CYP1A2 codes for an enzyme
that is composed of 516 amino acids.
A somewhat atypical aspect of the CYP1A2 gene is that
there are alleles of this gene that are inducible by smok-
ing tobacco or consuming cruciferous vegetables, such
as cabbage or Brussels sprouts. Consequently, patients
who smoke tobacco and have two alleles of CYP1A2
that are inducible by their smoking can be difficult to
maintain on 1A2 substrate medications. A relatively
common problem occurs when these patients are treated
with olanzapine or clozapine on an inpatient psychiatric
unit that does not allow them to smoke. When they
begin to smoke after they are discharged, their serum
level drops and their psychotic symptoms often reoccur.
In some populations of European ancestry, as many as
25% of the population can have an inducible ultrarapid
CYP1A2 phenotype.
Pharmacogenomic testing to identify 
variability in pharmacodynamic responses
A goal of individualized molecular psychopharmacology
is to identify medications for an individual patient that
will not only be safe, but will be effective. Progress in
making predictions of medication response has occurred,
and while the goal of being able to predict this response
with certainty has not been achieved, we can make
increasingly accurate probabilistic predictions of the
likelihood of response. Psychiatrists are familiar with this
limitation. While hundreds of randomized clinical trials
of psychotropic medications have been conducted to
identify effective psychotropic drugs, the results of these
trials only provide assurance that for a sample of
patients there is reasonable likelihood that the medica-
tion will be of more benefit than a placebo. While selec-
tive serotonin reuptake blockers are among the most
widely prescribed medications in the world, many
patients do not respond. Specifically, the largest clinical
effectiveness study of citalopram reported that less than
30% of the entire sample of patients experienced a com-
plete remission of their symptoms.
11 While the ultimate
goal of pharmacodynamically designed pharmacoge-
nomic testing is to identify a drug for a specific patient
that will definitely be effective, at the current stage of
our understanding, it is only possible to identify a med-
ication that is more likely to be effective.
The serotonin transporter gene (SLC6A4)
SLC6A4 is located on chromosome 17 and consists of 37
800 nucleotides. It codes for an enzyme that is composed
of 630 amino acids.
SLC6A4 is the most widely genotyped pharmacoge-
nomic “target” gene. A meta-analysis of studies of the
relationship between the more active long form of the
indel promoter variant of this gene and responses to
selective serotonin reuptake inhibitors
12 confirmed the
early finding that the long form is associated with a more
rapid and better response.
13 However, this has not con-
sistently been demonstrated in patients of Asian ances-
try.
14,15The importance of ancestral heritage has been fur-
ther demonstrated by multiple analyses of the large
STAR*D effective treatment study.
Analyses that did not consider ancestral background did
not demonstrate a significant association,
16 while those
that focused on patients who identified themselves as
“white” but not “Hispanic” did confirm the relationship
that patients who were homozygous for the more active
long form of the indel promoter polymorphism were
more likely to respond to citalopram. Other variants,
such as rs25531
17 and the second intronic VNTR
18 are
likely to influence the activity level of the gene and, con-
sequently, its response to medications that block its abil-
ity to reuptake serotonin in the synapses of the central
nervous system.
The serotonin receptor 2A gene (HTR2A)
HTR2A is located on chromosome 13 and consists of 62
663 nucleotides. Despite its large size, it codes for an
enzyme that is composed of only 471 amino acids.
There have been a series of studies examining the asso-
ciation between variants of HTR2A and antidepressant
response. A large study examining the response of
depressed patients of European ancestry to citalopram
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ated with having a copy of the adenine allele of
rs7997012.
19
Another study examining a different HTR2A variant,
rs6313, reported that patients who were homozygous for
the cytosine allele were less likely to tolerate taking
paroxetine than those who had one or more copies of
the thymine allele.
20
A series of studies have reported a better response to
clozapine in patients who had the thymine allele of
rs6313. The thymine allele of rs6313 has also been asso-
ciated with a lower risk for the development of
extrapyramidal side effects when taking antipsychotic
medications.
21-23
The serotonin receptor 2C gene (HTR2C)
HTR2C is a very large gene that is located on the X
chromosome and consists of 326 074 nucleotides.
However, it codes for a protein product that is composed
of only 458 amino acids.
Variations in the HTR2C gene have been associated
with a better clinical response to clozapine. Specifically,
patients with schizophrenia who have a copy of the cyto-
sine allele of rs6318 have achieved better control of their
psychotic symptoms than patients with the guanine
allele.
24,25 However, this same variant has been associated
with a higher risk for the development of extrapyrami-
dal side effects in patients who are taking typical antipsy-
chotic medications.
26
An increased risk for the development of weight gain
has been linked to a different HTR2C variant.
Specifically, the cytosine allele of rs518147 is associated
with increased weight gain, while the thymine allele is
conceptualized as providing protection against weight
gain.
27-29
The clinical utility of pharmacogenomic 
testing in psychiatric practice
Assessing the clinical utility of pharmacogenomic test-
ing is an ongoing process, given that the accuracy of
genotyping is continually improving, and new research
is identifying additional genetic variants that influence
medication responses. Reports of adverse responses to
2D6 substrate medications in patients with decreased
2D6 metabolic capacity support the use of testing at this
most basic level. Specifically, poor 2D6 metabolizers
have had quite dramatic side effects to 2D6 substrate
medications
3 and some toxic reactions have been
lethal.
30,31 However, there have been no large random-
ized clinical trials to demonstrate the clinical utility of
pharmacogenomic testing. Such trials would reinforce
the use of testing. However, it is unlikely that these tri-
als will ever be conducted because, by definition, they
are not designed to concentrate on those patients who
are the most likely to benefit from pharmacogenomic
testing. Trials that screen vulnerable populations and
identify patients at risk for suboptimal responses to med-
ications are a more efficient method to address the clin-
ical usefulness of testing patients with decreased meta-
bolic capacity. These screened patients could then be
enrolled in protocols designed to provide optimal
response for their specific genotypes and predicted phar-
macogenomic phenotypes.
Ethical considerations for pharmacogenomic
testing in psychiatric practice
The provision of pharmacogenomic testing involves rel-
atively few risks, but ethical safeguards are still impor-
tant to consider. These are essentially the same consid-
erations that are important to think through when
ordering any laboratory test that has the potential to
direct a treatment decision.
First, clinical pharmacogenomic testing requires obtain-
ing appropriate consent. This has become a guiding prin-
ciple for all diagnostic and therapeutic procedures.
Clinicians should provide the basic rationale for pro-
ceeding with pharmacogenomic testing so that their
patients have the opportunity to provide explicit
informed consent. 
Secondly, as a component of obtaining clinical consent,
it must be clear that clinical testing is a voluntary proce-
dure. This is true for virtually all clinical laboratory test-
ing with the relatively rare exceptions of mandatory test-
ing that can identify a condition with a potential
negative influence on the public health of the commu-
nity. A common example of compulsory testing is the
monitoring of infections in order to prevent contagion. 
A third principle is that clinicians must insure the confi-
dentiality of sensitive medical information that becomes
a part of the medical record of the patient. This is true
whether the information is derived from a pathological
specimen that reveals a malignant carcinoma or from
magnetic resonance imaging that demonstrates atrophy
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is the responsibility of the clinician.
Finally, any diagnostic medical procedure must have an
acceptable level of reliability. The degree of accuracy of
any clinical laboratory testing is dependent on a number
of key variables. Two of these variables are the serious-
ness of the prognosis for the patient if the test is positive
and the efficacy of available treatments. In designing the
treatment plan for a potentially lethal condition that is
likely to respond well to a relatively benign intervention
if it is administered early in the course of the illness, a
laboratory test with high sensitivity is desirable. The
most important objective in this situation is to identify
as quickly as possible those patients who will benefit
from treatment.
Future developments that will influence 
pharmacogenomic testing in 
psychiatric practice
In the 2009 presidential lecture of the American
Psychiatric Association, it was predicted that pharma-
cogenomic testing would become a part of everyday psy-
chiatric practice.
32 Ironically, in many academic health
centers, pharmacogenomic testing has been utilized since
2004—the time of the introduction of the AmpliChip.
Over the intervening years, early adopters have inte-
grated pharmacogenomic testing into their inpatient
protocols and ultimately into their outpatient practices.
However, this testing has not yet been included in many
clinical guidelines. 
Pharmacogenomic testing is an innovation, and it takes
time for innovations to become integrated into standard
practice. While it is difficult to predict with accuracy just
how quickly pharmacogenomic testing will become an
essential component of clinical psychopharmacological
practice, there is no question that this will happen.
Ironically, given advances in our ability to sequence genes
both rapidly and inexpensively, there will come a time in
the near future when most patients will know their 2D6
phenotype in the same way as today they know their
blood type. However, well before we reach a state of uni-
versal awareness of our informative genotypes, our
patients will no longer accept avoidable side effects, and
will demand basic pharmacogenomic testing prior to tak-
ing antidepressant or antipsychotic medications. ❏
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Pruebas farmacogenómicas en la práctica 
clínica psiquiátrica
La incorporación en psiquiatría clínica de las prue-
bas farmacogenómicas ha ocurrido rápidamente en
los últimos siete años. Inicialmente se identificaron
genes de enzimas metabolizadoras de fármacos,
como el gen del citocromo P450 2D6. La tipificación
del gen del citocromo P450 2D6 que es altamente
variable da la oportunidad actualmente a los clíni-
cos de identificar a los metabolizadores pobres y los
ultrarrápidos para las sustancias que son sustrato
del 2D6. Con posterioridad se ha podido disponer
en la práctica clínica de genes que influyen en la
respuesta farmacodinámica de los medicamentos.
Entre los primeros “genes blanco” estuvo el gen del
transportador de serotonina (SLC6A4), el cual tiene
variantes que han demostrado que influyen en la
respuesta clínica de los pacientes con ancestros
europeos cuando son tratados con inhibidores
selectivos de la recaptura de serotonina. La tipifi-
cación de algunos de los genes del receptor de sero-
tonina también está disponible para guiar la prác-
tica clínica. La cuantificación de la utilidad clínica de
las pruebas farmacogenómicas está en desarrollo y
se han establecido las consideraciones éticas para
su realización. Considerando la cada vez más clara
costo-eficacia de la tipificación génica, reciente-
mente se ha pronosticado que las pruebas farma-
cogenómicas se solicitarán de rutina para orientar
la selección y dosificación de los fármacos psicotró-
picos.  
Évaluation pharmacogénomique 
psychiatrique en pratique clinique
L’évaluation pharmacogénomique psychiatrique
s’est rapidement imposée en pratique clinique au
cours de ces 7 dernières années. Les gènes d’en-
zymes métabolisant les médicaments, comme le
cytochrome P450 2D6 (CYP2D6), ont d’abord été
identifiés. Le génotypage de ce gène très variable
permet maintenant aux cliniciens d’identifier des
métaboliseurs lents et des métaboliseurs ultrara-
pides des substrats du 2D6.  Des gènes influant sur
la réponse pharmacodynamique des médicaments
sont ensuite devenus disponibles en pratique cli-
nique. Parmi les premiers « gènes cibles », le gène
du transporteur de la sérotonine (SLC6A4) possède
des variants qui influent sur la réponse clinique des
patients d’ascendance européenne lorsqu’ils sont
traités avec des inhibiteurs sélectifs de la recapture
de la sérotonine. Le génotypage de certains gènes
du récepteur de la sérotonine est également dis-
ponible pour  guider la réponse clinique. La quan-
tification de l’utilité clinique de l’évaluation phar-
macogénomique évolue et fait l’objet de
considérations éthiques. Il a été  récemment prédit
qu’en raison de l’évidente rentabilité croissante du
génotypage, l’évaluation pharmacogénomique
devrait faire partie des examens de routine pour
sélectionner et ajuster la posologie des médica-
ments psychotropes.
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